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Available online 12 December 2015Fabry disease is ametabolic and lysosomal storage disorder causedby the functional defect of theα-galactosidase
A enzyme; this defect is due to mutations in the GLA gene, that is composed of seven exons and is located on the
long arm of the X-chromosome (Xq21–22).
The enzymatic deﬁcit is responsible for the accumulation of glycosphingolipids in lysosomes of different cellular
types, mainly in those ones of vascular endothelium. It consequently causes a cellular and microvascular
dysfunction.
In this paper, we described ﬁve novel mutations in the GLA gene, related to absent enzymatic activity and typical
manifestations of Fabry disease.We identiﬁed threemutations (c.846_847delTC, p.E341X and p.C382X) that lead
to the introduction of a stop codon in positions 297, 341 and 382. Moreover we found a missense mutation
(p.R227P) in the exon 5 of the GLA gene and a single point mutation (c.639+5 GNT) occurring ﬁve base pairs
beyond the end of the exon 4. These mutations have never been found in our group of healthy control subjects
N2300.
The studied patients presented some clinical manifestations, such as cornea verticillata, hypo-anhidrosis, left
ventricular hypertrophy, cerebrovascular disorders and renal failure, that, considering the null enzymatic activ-
ity, suggest that the new mutations reported here are related to the classic form of Fabry disease.
The identiﬁcation of novel mutations in patients with symptomatology referable to FD increases the molecular
knowledge of the GLA gene and it gives clinicians an important support for the proper diagnosis of the disease.
© 2015 Elsevier B.V. All rights reserved.Keywords:
Fabry disease
Alpha-galactosidase A
c.846_847delTC
p.E341X
p.C382X
p.R227P
c.639+5GNT1. Introduction
Fabry disease (FD) is a hereditary, X-linked, progressive and
multisystemic lysosomal storage disease. It is ametabolic disorder caused
by functional deﬁcit of the α-galactosidase A enzyme (α-GAL A) (Brady
et al., 1967). This deﬁcit is responsible for the alteration of themetabolism
of some glycosphingolipids, mainly globotriaosylceramide (GB3) and
globotriaosylsphingosine (Lyso-GB3), which consequently build up in, α-galactosidase A; GB3,
sine; GLA, GLA gene; ND, not
splicing enhancer.
Molecular Immunology (IBIM),
lermo, Italy.lysosomes of different cellular types, mostly in vascular endothelium
cells (Desnick et al., 2001).
Clinical manifestations of the disease are slowly progressive, with a
variable age of onset, severity, and course. Usually, it occurs during
childhood or early adolescence manifesting angiokeratomas, lenticular
and corneal opacity, microalbuminuria or proteinuria, and symptoms
involving the peripheral nervous system. With the age, the disease
leads to a gradually worsening of renal conditions and to cardiovascular
involvement and cerebrovascularmanifestations. These symptoms, or a
combination of them, can cause the premature death of the patients
during their fourth or ﬁfth decade of life (Germain, 2010). Female
patients, due to the random inactivation of the X-chromosome, usually
present a milder and more variable symptomatology in comparison to
male subjects (Dobrovolny et al., 2005). In addition to the classic form,
atypical variants of Fabry disease have been described (Nakao et al.,
101C. Zizzo et al. / Gene 578 (2016) 100–1041995). These variants, that represent the 70% of Fabry patients, usually
manifest a mild and late-onset phenotype and a non-speciﬁc symptom-
atology that make the diagnosis difﬁcult. For this reason, the disease in
these patients can be diagnosed in adulthood, when the irreversible
impairment of internal organs already occurred (Lidove et al., 2012).
Retrospective studies highlighted a delay in diagnosing FD in about
40% of male patients and 70% of female patients (Hoffmann and
Mayatepek, 2009).
The disease is considered rare, with an incidence estimated about
1:40000 in general population. However, recent neonatal screening
studies have shown a higher incidence: about 1 in 3100 among new-
born males in Italy (Spada et al., 2006) and 1 in 1500 among newborn
males in Taiwan (Hwu et al., 2009).
Considering its etiology, Fabry disease is a lysosomal enzymopathy
caused by mutations in the GLA gene (GLA), encoding the α-GAL A, lo-
cated on the long arm of the X-chromosome (Xq21–22) (Germain,
2010). To date, more than 770 mutations in the coding GLA regions
were described in Fabry patients (Human Gene Mutation Database,
www.hgmd.org). However, there is not a clear genotype–phenotype
correlation.
In this paper ﬁve mutations (c.846_847delTC, p.E341X, p.C382X,
p.R227P, c.639+5GNT) found in the GLA gene of patients with clinical
diagnosis of Fabry disease are described for the ﬁrst time. The identiﬁca-
tion of novel mutations in patients with symptomatology referable to
FD increases the molecular knowledge of the GLA gene and it gives cli-
nicians an important support for the proper diagnosis of the disease.
Moreover, the genetic investigation on the relatives of patients suffering
from FD allows us to detect oligo- or pre-symptomatic subjects who can
start as early as possible the speciﬁc therapy, before the organ involve-
ment becomes irreversible.
2. Material and methods
2.1. Patient specimens
Peripheral blood was collected, using EDTA as an anticoagulant,
from patients with clinical manifestations related to FD symptomatolo-
gy. The studywas approved by theHospital Ethics Committee of Univer-
sity of Palermo, and signed informed consent was obtained from all
participants.
2.2. DNA isolation
DNA samples were isolated from whole blood by column extraction
(GenElute Blood Genomic DNA Kit, Miniprep, Sigma-Aldrich, USA), and
their concentrations were determined using a spectrophotometer.
2.3. High resolution melting analysis and DNA sequencing
High resolution melting analysis was performed on DNA samples
using the Light Cycler 480 system (Roche Applied Science, Germany).
Seven pairs of primerswere designed for the analysis of seven target re-
gions containing the seven exons of the GLA gene and the regulatoryTable 1
Clinical and molecular data of the ﬁve index cases. In bold, values below the normal range. No
Index
case
Gender/age GLA
mutation
Enzymatic
activity
Acroparesthesias Angiokeratomas
1 F/24 c.846_847del AG 0.3 + +
2 F/62 p.E341X 1.6 − +
3 F/44 p.C382X 3.6 + −
4 F/59 p.R227P 2.3 − −
5 M/43 c.639+5GNT 0.2 + +sequences ﬂanking them. In order to ensure the detection of
hemizygotes, male subjects were analyzed by adding a wild type DNA
counterpart, in a 1:1 quantity ratio, to their DNA sample to produce ar-
tiﬁcial heterozygotes and induce heteroduplex formation.
PCR products presenting melting curves different in position or
shape from those of the wild type control were puriﬁed and sequenced
to identify suspected mutations, using automated DNA sequencer at
BMR Genomics.2.4. Alpha-galactosidase activity assay
Alpha-galactosidase A activity was determined by the Dried Blood
Filter Paper test described by Chamoles et al. (2001), with the following
modiﬁcations: spot of 5.5 μl of blood in 6-mmdiameter circle paperwas
placed into a 96-well plate suitable for ﬂuorimetric assays and incubat-
ed for 16 h at 37 °C in a thermomixer; the reaction was terminated by
the addition of 250 μl of 0.1 mol/l ethylenediamine (pH 11.4). The ﬂuo-
rescence of backgroundwhich is not due to the speciﬁc enzymatic activ-
ity, was determined for each sample, doing another reaction in the
presence of 0.15 nmol/l 1-deoxygalactonojirimycin (DGJ, the inhibitor
of alpha galactosidase A) in 0.15 mol/l citrate phosphate buffer
(pH 4.4). This background was subtracted from the ﬂuorescence of the
sample.3. Results
In this paper, we describe ﬁve novel mutations that we found in pa-
tients with clinical diagnosis of Fabry disease, in whom we performed
molecular analyses (Table 1). These alterations are not present in the
Human Gene Mutation Database (http://www.hgmd.org) and in Fabry
disease databases.We named the ﬁvemutations according to the guide-
lines for mutation nomenclature recommended by the Human Genome
Variation Society (www.hgvs.org/mutnomen).
Where it was possible, we also extended the genetic and enzymatic
analyses of alpha galactosidase A to the relatives of probands (Table 2).3.1. Index case 1
Patient 1 is a 24-year-old girl that manifested angiokeratomas and
burning pain in hands and feet since childhood. Fabry disease was
suspected after that the clinician found a left ventricularwall thickening
typical of Fabry disease.3.1.1. Molecular diagnosis (index case 1)
The genetic analysis of theGLAgene in this patient allowedus to iden-
tify a new two base pair deletion (c.846_847delTC) in the exon 6 of the
gene. This small deletion causes a frameshift causing a stop codon at
position 297 resulting in a protein of 296 amino acids rather than of
429; the DBFP test showed no enzymatic activity (0.3 nmol/h/ml).rmal values of α-galactosidase A activity assayed in whole blood are N3.0 nmol/h/ml.
Cardiac
manifestations
Renal
manifestations
Neurological
manifestations
Other signs
+ − − −
+ + + Cornea verticillata
+ + + Cornea verticillata, fatigue,
gastrointestinal manifestations,
recurrent fevers
+ + − Anhidrosis
+ + − Recurrent fever, heat and cold
intolerance, hypohidrosis, fatigue
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Patient 2 is a 62-year-oldwoman, affected by hypertension, diabetes
and chronic renal failure. She experienced two strokes in three years
and she underwent several cardiovascular controls for atrial ﬁbrillation
and hypertensive heart disease: these highlighted a hypertrophic car-
diomyopathy. She also manifested cornea verticillata in the right eye
and cataract in the left one and she showed angiokeratomas of the
vulvar region. All these clinical data led clinicians to hypothesize the
diagnosis of Fabry disease (Table 2).
In addition, her 35-year-old daughter showed early signs of cornea
verticillata in both eyes and microalbuminuria; cardiovascular and der-
matologic examinations resulted negative. The proband's grandson is a
child aged 8 who was apparently asymptomatic, though he showed
anhidrosis and acroparesthesias, peculiar manifestations of Fabry dis-
ease in pediatric age (Table 2).
3.2.1. Molecular diagnosis (index case 2)
The clinical suspect of Fabry disease encouraged us to perform
the molecular analyses in this patient and her relatives (Table 2).
The genetic analysis of GLA revealed a novel non-sense mutation
(c.1021GNT). It is a GNT transversion at position 1021 of the GLA
cDNA that introduces a stop codon at position 341 resulting in a truncat-
ed protein (p.E341X). Enzymatic activity resulted 1.6 nmol/h/ml in the
proband, belownormal values ofα-galactosidase A activity.We extend-
ed the molecular study to other relatives and we found the samemuta-
tion in proband's daughter (her enzymatic activity was in the normal
range) and in one of the two grandchildren, who showed 0 activity
(Table 2).
3.3. Index case 3
Patient 3 is a 44-year-old woman, who came to our examination
after the casual ﬁnding of proteinuria and albuminuria. The woman
showed a clinical history of acroparesthesias, fatigue, recurrent fevers
and gastrointestinal manifestations in childhood, and she hadmanifest-
ed for some years cardiac arrhythmia, hearing loss, tinnitus and recur-
rent headaches. Moreover, she had received an initial diagnosis of
rheumatoid arthritis. After the clinical suspect of Fabry disease, clini-
cians performed ocular examination that revealed cornea verticillata,
typical of Fabry disease (Table 2).
3.3.1. Molecular diagnosis (index case 3)
The genetic analysis of GLA revealed a novel non-sense mutation in
the exon 7 of the gene (c.1146CNA). It is a CNA transversion at position
1146 of the GLA cDNA that introduces a stop codon at position 382
resulting in a truncated protein (p.C382X). The analysis of enzymatic ac-
tivity was 3.6 nmol/h/ml, just above the normal range (normal values of
alpha galactosidase A activity assayed in whole blood are N3.0 nmol/h/
ml). This is plausible considering that this patient is a female. We also
performed the genetic and enzymatic study in the 11-year-old
proband's daughter, who manifested fatigue and recurrent headaches
(Table 2).We found the samemutation of hermother and the enzymat-
ic activity resulted 2.6 nmol/h/ml, below the normal range.
3.4. Index case 4
Patient 4 is a 59-year-old woman with modest proteinuria and left
ventricular hypertrophy. Moreover, she reported anhidrosis, which ap-
peared in childhood. The patient has a son (27 years old) and a daughter
(30 years old): the son underwent dialysis after the incidental ﬁnding of
impaired renal function; the daughter suffered from abdominal pain
and gastrointestinal manifestations, and she also reportedmild protein-
uria. Moreover, the patient's brother died at the age of 49 for acutemyo-
cardial infarction (Table 2).
Fig. 1. Alignment of wild-type human α-Gal A amino acids with other organisms
sequences. The rectangle indicates the amino acid at position 227 that we found mutated
in the index case.
103C. Zizzo et al. / Gene 578 (2016) 100–1043.4.1. Molecular diagnosis (index case 4)
After the clinical suspect of Fabry disease, we performed the analysis
of seven exons of the GLA gene and the intronic regions ﬂanking them.
We found the novel mutation c.680GNC that causes the arginine to pro-
line substitution at amino acid 227 of the protein (p.R227P). Enzymatic
activity resulted 2.3 nmol/h/ml (normal values of α-galactosidase A ac-
tivity in whole blood are N3.0 nmol/h/ml).
We also extended the molecular study to other members of family
(Table 2). Three other family members showed the same mutation:
the patient's son (enzymatic activity 0 nmol/h/ml), the patient's daugh-
ter (enzymatic activity 2.8 nmol/h/ml) and also the patient's niece,
daughter of the patient's brother who died at the age of 49 for acute
myocardial infarction. In this last young woman, the enzymatic activity
resulted in the normal range (4.3 nmol/h/ml), although she already
manifested slight left ventricular hypertrophy and recurrent fevers
arisen in early age.
3.5. Index case 5
Patient 5 is a 43-year-old man. After the incidental ﬁnding of severe
renal failure, he underwent peritoneal dialysis for 4 years; then, he
underwent kidney transplantation. The 45-year-old brother of this pa-
tient had a similar clinical history: renal failure of unknown cause and
subsequent kidney transplantation. Both brothers showed a clinical his-
tory of recurrent fevers in childhood, acroparesthesias, intolerance to
heat and cold, hypohidrosis and fatigue.
They also had “angiocheratoma diffusum” since youth. Considering
the typical clinical history andmedical records, Fabry diseasewas inves-
tigated (Table 2). The evaluation of the disease was extended to their
47-year-old sister, who manifested only intolerance to heat and cold,
and the 17-year-old proband's daughter, who had recurrent fever and
acroparesthesias.
3.5.1. Molecular diagnosis (index case 5)
Molecular studies showed a novel point mutation (c.639+5GNT)
in the intron–exon splice junction, 5 base pairs downstream from
the end of exon 4 of the GLA gene; enzymatic activity was absent
(0.2 nmol/h/ml) in the proband.
The genetic and enzymatic analyses were extended to other family
members and, among these, three patients with the same mutation
were identiﬁed (Table 2). The three affected subjects were: the
proband's brother, who had 0.6 nmol/h/ml enzymatic activity, the
proband's daughter, who had 0.1 nmol/h/ml enzymatic activity; the
proband's sister, who showed normal values of α-galactosidase A
activity.
4. Discussion
In this paper, we described ﬁve novel mutations (c.846_847delTC,
p.E341X, p.C382X, p.R227P, c.639+5GNT) that we found in unrelated
patients, conﬁrming the genetic heterogeneity observed in subjects
affected by Fabry disease. These mutations are not present in the
Human Gene Mutation Database (http://www.hgmd.org) and in Fabry
disease databases. Where it was possible, we also extended the genetic
and enzymatic analyses of alpha galactosidase A to the relatives of
probands.
The mutations responsible for the introduction of a premature stop
codon (c.846_847delTC, p.E341X, p.C382X) were found in patients af-
fected by the classical phenotype of Fabry disease. This is plausible be-
cause these mutations result in truncated and non-functional proteins.
In fact, the resulting proteins lack almost one third, one ﬁfth and one
eighth of the wild-type protein of 429 amino acids, respectively.
The loss of function in these proteins was also proved by the absent
enzymatic activity, observed in the onlymalewith amutation causing a
stop codon. He is an 8-year-old child, grandson of the index case 2, who
was affected by p.E341X mutation and manifested anhidrosis andacroparesthesias. The other subjects with mutations resulting in a stop
codon, who were all females, had values of enzymatic activity below
the normal range (three of them) or normal (two of them). This vari-
ability is due to the chromosome X inactivation. Thus, on the basis of
which chromosome is silenced, (mutated one or wt one) the resulting
protein will be a functional or an inactive enzyme. Moreover, until a
few years ago the inactivation of the X chromosome was thought to
be random, but today this concept has been revised. It was observed
that in some females, the X chromosome inactivation is not random in
all tissues but some of them show a skewed inactivation to the wild
type X chromosome or the mutated one — phenomenon that, still
today, is without an explanation (Echevarria et al., 2015). This results
in a great clinical heterogeneity ranging from the absence of the mani-
festations to a severity comparable to the one of the males affected by
Fabry disease (Whybra et al., 2001; MacDermot et al., 2001; Wilcox
et al., 2008).
Themissensemutation described in this article is also responsible of
Fabry phenotype. Patient 4 with p.R227P mutation was a 59-year-old
woman. Although the advanced age, she presented only a mild protein-
uria and a marked left ventricular hypertrophy, but she had a family
history strongly suggestive of Fabry disease: her brother died at the
age of 49 for acute myocardial infarction.
Moreover, according to Polyphen 2 (http://genetics.bwh.harvard.
edu/pph2), a tool that predicts possible impact of an amino acid substi-
tution on the structure and function of a human protein, the mutation
p.R227P is probably damaging. It also predicts that R227 is highly con-
served throughout the evolution (Fig. 1). The amino acid is not localized
in the binding site or in the catalytic domain, however it is closely near
the latter. In Fabry database (http://fabry-database.org/), a different
mutation affecting this amino acid (p.R227Q) is predicted to cause
the classical form of Fabry disease, probably because of a structural
change on active site residues. Moreover mutations in other amino
acids ﬂanking R227 (p.W226R, p.N224S and p.N224D) are responsible
for classic phenotype of Fabry disease (Ashton-Prolla et al., 2000;
Guffon et al., 1998). These data, in addition to the null activity that we
found in a male with p.R227P, conﬁrm the pathogenic role of this
mutation.
Moreover, in this paper, we describe a family, the proband and his
three relatives with the c.639+5GNT mutation. It is a GNT transition
occurring 5 base pairs downstream from the end of exon 4 of the GLA
gene, in a regulation splicing site. The subjects, in whom this mutation
was found, manifested typical signs and symptoms of Fabry disease,
such as acroparesthesias, heat and cold intolerance, recurrent fever,
angiokeratomas and renal failure. Moreover, the enzyme activity result-
ed absent or strongly reduced in three out of four subjects, instead in a
femalewith the samemutation, because of X-chromosome inactivation,
the enzyme activity was normal. This mutation is not in the coding
region of the GLA gene but it is the only mutation that we found in
and no enzyme activity. It was never found in more than 2300 healthy
control subjects.
104 C. Zizzo et al. / Gene 578 (2016) 100–104Using RegRNA 2.0 (http://regrna2.mbc.nctu.edu.tw/), a computa-
tional platform that is able to ﬁnd hypothetical regulatory sites in a
DNA sequence, we found that the mutation occurs in a putative site of
splicing regulation. The guanine in position c.639+5 of the GLA gene
is included in a sequence of 5 bases that is predicted to be a putative in-
tron splicing enhancer (ISE sequence) by RegRNA program. The GNT
substitution in this position would cause the loss of function of ISE, be-
cause of the modiﬁcation of this sequence. Mutations in these sites
could play a role in the synthesis of GLA mRNA and in the (qualitative
and quantitative) production of α-galactosidase A. It is well known in
literature that the alternative splicing products of mRNAs may be locat-
ed in different cell types. It was estimated that the aberrant splicing of
mRNAs causes the 15% of human genetic diseases (Tazi et al., 2009).
All the patients studied in this paper, showed symptoms referable to
the classical form of Fabry disease with ﬁrst manifestations, such as
acroparesthesias, fatigability, gastrointestinal manifestations and
hypo-anhidrosis in childhood. However, all the index cases were diag-
nosed in adulthood when one or more appreciable clinical manifesta-
tions such as ictus, renal failure and left ventricular hypertrophy led
the clinicians to study Fabry disease.
The main reasons of the missed diagnoses of Fabry disease are due
to the phenotypic variability — both between related patients and be-
tween unrelated ones. Secondly, several clinical features of Fabry disease
are usually present in the general population, such as neuropathic and
abdominal pain, headache, tinnitus, hearing loss, gastrointestinal mani-
festations, renal and cardiovascular diseases (Ries and Gal, 2006).
5. Conclusion
The genotype–phenotype correlation is still unclear in Fabry disease.
In fact, some mutations can cause different phenotypes both between
related subjects and between unrelated patients, suggesting the exis-
tence of genetic and/or environmental factors that could affect the se-
verity of the disease. This correlation is also complicated by several
factors such as the high number of privatemutations and the phenotyp-
ic heterogeneity associated to the same mutation. Moreover, patients
with Fabry disease can develop symptoms related to the disease that
are observed with high prevalence in the general population (Ries and
Gal, 2006; Schäfer et al., 2005).
Considering the clinical point of view, Fabry disease should be con-
sidered in patients with atypical clinical course, uncertain diagnosis, or
clinical picture with systemic involvement that is not clear, in particular
when a clinical family history is positive. This clinical approach would
help to limit themisdiagnosis between Fabry disease and other system-
ic disorders that aremore common.Moreover, it could contribute to re-
duce the time elapsing between the onset of the ﬁrst symptoms and the
proper diagnosis of Fabry disease, avoiding useless treatments for the
patients and starting the therapy for the disease that to date is available.
The data in literature show the importance of speciﬁc therapeutic inter-
vention made as early as possible, before the organ involvement be-
comes irreversible (Pisani et al., 2014, 2012, 2015, 2005; Spinelli et al.,
2004).
Acknowledgments
The ﬁnancial support for the conduct of the research andpreparation
of the article was provided by the National Research Council (CNR)
(ME.P01.014.008).References
Ashton-Prolla, P., Tong, B., Shabbeer, J., Astrin, K.H., Eng, C.M., Desnick, R.J., 2000.
Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene
and genotype/phenotype correlations in severely and mildly affected hemizygotes
and heterozygotes. J. Investig. Med. 48 (4), 227–235.
Brady, R.O., Gal, A.E., Bradley, R.M., Martensson, E., Warshaw, A.L., Laster, L., 1967. Enzy-
matic defect in Fabry's disease. Ceramidetrihexosidase deﬁciency. N. Engl. J. Med.
276 (21), 1163–1167.
Chamoles, N.A., Blanco, M., Gaggioli, D., 2001. Fabry disease: enzymatic diagnosis in dried
blood spots on ﬁlter paper. Clin. Chim. Acta 308 (1–2), 195–196.
Desnick, R.J., Ioannou, Y.A., Eng, C.M., 2001. Alpha-galactosidase A deﬁciency: Fabry dis-
ease. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.), The Metabolic and Mo-
lecular Basis of Inherited Disease, eighth ed. McGraw-Hill, New York, pp. 3733–3774.
Dobrovolny, R., Dvorakova, L., Ledvinova, J., Magage, S., Bultas, J., Lubanda, J.C., Elleder, M.,
Karetova, D., Pavlikova, M., Hrebicek, M., 2005. Relationship between X-inactivation
and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-
galactosidase A gene in the Czech and Slovak population. J. Mol. Med. 83 (8), 647–654.
Echevarria, L., Benistan, K., Toussaint, A., Dubourg, O., Hagege, A.A., Eladari, D., Jabbour, F.,
Beldjord, C., De Mazancourt, P., Germain, D.P., 2015. X-chromosome inactivation in
female patients with Fabry disease. Clin Genet http://dx.doi.org/10.1111/cge.12613
(Epub ahead of print).
Germain, D.P., 2010. Fabry disease. Orphanet J. Rare Dis. 5, 30.
Guffon, N., Froissart, R., Chevalier-Porst, F., Maire, I., 1998. Mutation analysis in 11 French
patients with Fabry disease. Hum Mutat (Suppl. 1), S288–S290.
Hoffmann, B., Mayatepek, E., 2009. Fabry disease — often seen, rarely diagnosed. Dtsch.
Arztebl. Int. 106 (26), 440–447.
Hwu, W.L., Chien, Y.H., Lee, N.C., Chiang, S.C., Dobrovolny, R., Huang, A.C., Yeh, H.Y., Chao,
M.C., Lin, S.J., Kitagawa, T., Desnick, R.J., Hsu, L.W., 2009. Newborn screening for Fabry
disease in Taiwan reveals a high incidence of the later-onset GLA mutation
c.936+919GNA (IVS4+919GNA). Hum. Mutat. 30 (10), 1397–1405.
Lidove, O., Kaminsky, P., Hachulla, E., Leguy-Seguin, V., Lavigne, C., Marie, I., Maillot, F.,
Serratrice, C., Masseau, A., Chérin, P., Cabane, J., Noel, E., FIMeD investigators, 2012.
Fabry disease ‘The NewGreat Imposter’: results of the French Observatoire in Internal
Medicine Departments (FIMeD). Clin. Genet. 81 (6), 571–577.
MacDermot, K.D., Holmes, A., Miners, A.H., 2001. Anderson–Fabry disease: clinical mani-
festations and impact of disease in a cohort of 60 obligate carrier females. J. Med.
Genet. 38 (11), 769–775.
Nakao, S., Takenaka, T., Maeda, M., Kodama, C., Tanaka, A., Tahara, M., Yoshida, A.,
Kuriyama, M., Hayashibe, H., Sakuraba, H., Tanaka, H., 1995. An atypical variant of
Fabry's disease in men with left ventricular hypertrophy. N. Engl. J. Med. 333 (5),
288–293.
Pisani, A., Spinelli, L., Sabbatini, M., Andreucci, M.V., Procaccini, D., Abbaterusso, C.,
Pasquali, S., Savoldi, S., Comotti, C., Cianciaruso, B., 2005. Enzyme replacement thera-
py in Fabry disease patients undergoing dialysis: effects on quality of life and organ
involvement. Am. J. Kidney Dis. 46 (1), 120–127.
Pisani, A., Visciano, B., Roux, G.D., Sabbatini, M., Porto, C., Parenti, G., Imbriaco, M., 2012.
Enzyme replacement therapy in patients with Fabry disease: state of the art
and review of the literature. Mol. Genet. Metab. 107 (3), 267–275.
Pisani, A., Visciano, B., Imbriaco, M., Di Nuzzi, A., Mancini, A., Marchetiello, C., Riccio, E.,
2014. The kidney in Fabry's disease. Clin. Genet. 86 (4), 301–309.
Pisani, A., Sabbatini, M., Duro, G., Colomba, P., Riccio, E., 2015. Antiproteinuric effect of
add-on paricalcitol in Fabry disease patients: a prospective observational study.
Nephrol. Dial. Transplant. 30 (4), 661–666.
Ries, M., Gal, A., 2006. Genotype–phenotype correlation in Fabry disease. In: Mehta, A.,
Beck, M., Sunder-Plassmann, G. (Eds.), Fabry Disease: Perspectives From 5 Years of
FOS. Oxford PharmaGenesis, Oxford (Chapter 34).
Schäfer, E., Baron, K., Widmer, U., Deegan, P., Neumann, H.P., Sunder-Plassmann, G.,
Johansson, J.O., Whybra, C., Ries, M., Pastores, G.M., Mehta, A., Beck, M., Gal, A.,
2005. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease.
Hum. Mutat. 25 (4), 412.
Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A.,
Desnick, R.J., 2006. High incidence of later-onset Fabry disease revealed by newborn
screening. Am. J. Hum. Genet. 79 (1), 31–40.
Spinelli, L., Pisani, A., Sabbatini, M., Petretta, M., Andreucci, M.V., Procaccini, D., Lo Surdo,
N., Federico, S., Cianciaruso, B., 2004. Enzyme replacement therapy with agalsidase
beta improves cardiac involvement in Fabry's disease. Clin Genet 66 (2), 158–165.
Tazi, J., Bakkour, N., Stamm, S., 2009. Alternative splicing and disease. Biochim. Biophys.
Acta 1792 (1), 14–26.
Whybra, C., Kampmann, C., Willers, I., Davies, J., Winchester, B., Kriegsmann, J., Brühl, K.,
Gal, A., Bunge, S., Beck, M., 2001. Anderson–Fabry disease: clinical manifestations of
disease in female heterozygotes. J. Inherit. Metab. Dis. 24 (7), 715–724.
Wilcox, W.R., Oliveira, J.P., Hopkin, R.J., Ortiz, A., Banikazemi, M., Feldt-Rasmussen, U.,
Sims, K., Waldek, S., Pastores, G.M., Lee, P., Eng, C.M., Marodi, L., Stanford, K.E.,
Breunig, F., Wanner, C., Warnock, D.G., Lemay, R.M., Germain, D.P., 2008. Fabry registry.
Females with Fabry disease frequently have major organ involvement: lessons from
the Fabry registry. Mol. Genet. Metab. 93 (2), 112–128.
